Search results
Showing 2161 to 2175 of 2548 results for methods
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development Reference number: GID-TA10886 Expected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
In development Reference number: GID-TA11117 Expected publication date: TBC
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
Discontinued Reference number: GID-TAG391
Discontinued Reference number: GID-TA10531
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Discontinued Reference number: GID-TA10933
VEST external stent for coronary artery bypass grafts (MIB115)
NICE has developed a medtech innovation briefing (MIB) on the VEST external stent for coronary artery bypass grafts .
Suture fixation of acute disruption of the distal tibiofibular syndesmosis (IPG521)
Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.
Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]
Discontinued Reference number: GID-TAG420
Discontinued Reference number: GID-TAG368
Discontinued Reference number: GID-TA10567
In development Reference number: GID-TA10391 Expected publication date: TBC